预约演示
更新于：2025-06-18
Icaritin
阿可拉定
更新于：2025-06-18
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2022-01-10), |
最高研发阶段(中国)批准上市 |
特殊审评附条件批准 (中国)、优先审评 (中国) |
登录后查看时间轴
关联
24
项与 阿可拉定 相关的临床试验CTR20251930
淫羊藿素软胶囊在中国健康受试者中的药代动力学研究
ChiCTR2500101716
Pharmacokinetic Study of Icaritin Soft Capsules in Healthy Chinese Subjects
NCT06825546
A Multicenter Study Assessing the Efficacy and Safety of Icaritin in Combination With AG Chemotherapy Versus AG Chemotherapy Alone in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
100 项与 阿可拉定 相关的临床结果
登录后查看更多信息
100 项与 阿可拉定 相关的转化医学
登录后查看更多信息
100 项与 阿可拉定 相关的专利（医药）
登录后查看更多信息
380
项与 阿可拉定 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases
Article
作者: Lu, Jianguo ; Zhang, Yizhuo ; Dong, Xinyu ; Cao, Yanlong ; Hong, Defei ; Jiang, Guixing ; Liu, Xiaolong
BACKGROUND:
Pancreatic cancer is very difficult to detect in its early stages, and its rapid progression and poor prognosis make it a significant therapeutic challenge. Existing treatment modalities, whether standalone or combined, offer limited efficacy, highlighting an urgent need for more effective and less toxic therapeutic strategies.
PATIENTS:
We analyze six cases of pancreatic cancer, each undergoing a novel treatment regimen integrating chemotherapy, targeted therapy, immune therapy, and icaritin.
RESULTS:
The outcomes demonstrate varying degrees of improvement in all cases. Partial responses were observed in cases 1 and 3, with some tumor shrinkage. Cases 4 and 5 showed limited relief following a slight decrease in tumor size. In cases 2 and 6, no significant progression of the lesion was observed. These results highlight the potential efficacy of this multifaceted approach.
CONCLUSION:
Integrating icaritin with chemotherapy, immunotherapy, and/or targeted therapies shows potential as an exploratory approach in managing advanced, locally progressive, or metastatic pancreatic cancer, though further validation is required.
2025-08-01FREE RADICAL BIOLOGY AND MEDICINE
Icaritin promotes brain functional rehabilitation in ischemic stroke rats by regulating astrocyte activation and polarization via GPER
Article
作者: Zhang, Limei ; Luo, Li ; Huang, Zhihua ; Yu, Zining ; Fang, Shicai ; Tang, Shi ; Zhang, Qian ; Liu, Gaigai ; Li, Liangdong ; Cao, Xingling ; Su, Guangjun ; Huang, Cheng
BACKGROUND:
Cerebral ischemic injury induces the polarization of astrocytes toward two different phenotypes, i.e., the proinflammatory A1 phenotype and the protective, anti-inflammatory A2 phenotype, affects the prognosis of cerebral ischemia. To explore the neuroprotective effect of phytoestrogens ICT on cerebral ischemic rehabilitation and the preliminary mechanism of regulating astrocyte polarization.
METHODS:
Transient middle cerebral artery occlusion (tMCAO)/reperfusion was performed on rats and then treated with ICT (i.p.) once daily for 28 days. Intervention of GPER specific inhibitor G15 was repeated. The body weight, Garcia JH scale, right/left brain weight ratio, CatWalk gait test and Y maze test to assess overall neural function in rats. Inflammatory factors in ischemic cortical were detected by Western blotting. The number of newborn neurons was observed by BrdU staining, and the double immunofluorescence staining and Western blotting to evaluated the activation and A1 and A2 polarization of astrocytes.
RESULTS:
The results showed that ICT treatment markedly perfected functional outcomes on a long-term basis after ischemic stroke, it also improved learning and memory and gait. ICT inhibited the polarization of A1 type astrocytes and promoted the polarization of A2 type astrocytes, promote neuron regeneration in hippocampus DG region. G15 removes some of the protective effects of ICT.
CONCLUSIONS:
The experimental results show that ICT exerts neuroprotective effects and regulates astrocyte polarization through GPER, suggesting that it may be a potential therapeutic agent for ischemic stroke during the recovery period.
2025-08-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Comprehensive characterization of the chemical composition of Ela tablet and its metabolites, with molecular docking screening of potential bioactive components for erectile dysfunction treatment
Article
作者: Liu, Yongqiang ; Xi, Ruqi ; Aisa, Haji Akber ; Abdulla, Rahima
Erectile dysfunction (ED) is a disorder involving both physiological and psychological implications, and phosphodiesterase 5 (PDE5) inhibitors serve as the primary treatment. The Ela tablet, a traditional herbal formulation, has demonstrated promising PDE5 inhibitory effects, yet its bioactive constituents and metabolic fate remain unclear. A four-step strategy combining offline two-dimensional supercritical fluid chromatography (SFC) and ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS) was established to characterize the chemical composition of the Ela tablet. This was followed by in vivo metabolic profiling in rats to determine prototype compounds and metabolites. Molecular docking analysis was then conducted to evaluate the interaction of blood-absorbable prototype compounds with PDE5. A total of 362 compounds were identified, including flavonoids, alkaloids, terpenoids, organic acids and other classes of compounds. In vivo metabolic profiling revealed 70 compounds of prototype and metabolites, with hydrolysis and glucuronidation as the predominant metabolic pathway. Icaritin glycoside analogs underwent extensive metabolism producing Icaritin glucuronide conjugates as the major circulating forms, while N-alkylamides primarily remained in their prototype state. Molecular docking analysis revealed N-isobutyl-(2E,4E)-tetradecadienamide, Anacyclin, Dodeca-2E,4E-dienoic acid isobutylamide, Pellitorine, N-isobutyl-2-6-8-decatrienamide, Icaritin, and Desmethylicaritin as potential PDE5 inhibitors. These findings provide insights into the metabolic transformation and pharmacological mechanisms of the Ela tablet, supporting its potential clinical application in ED treatment. Future research should focus on pharmacokinetics, mechanistic validation, and clinical evaluation to further establish its therapeutic efficacy.
100 项与 阿可拉定 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不可切除的肝细胞癌 | 中国 | 2022-01-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期肝细胞癌 | 临床3期 | 中国 | 2017-09-08 | |
| 乙型肝炎病毒相关肝细胞癌 | 临床3期 | 中国 | 2017-09-08 | |
| 肿瘤 | 临床1期 | 中国 | 2022-01-30 | |
| 晚期癌症 | 临床1期 | 中国 | 2011-11-28 | |
| 晚期恶性实体瘤 | 临床1期 | 中国 | 2011-11-01 | |
| 晚期乳腺癌 | 临床1期 | 中国 | 2010-11-01 | |
| 转移性乳腺癌 | 临床1期 | 中国 | 2010-11-01 | |
| 晚期胰腺导管腺癌 | 临床阶段不明 | 中国 | - | |
| 错配修复缺陷或微卫星高度不稳定性结直肠癌 | 临床申请批准 | 中国 | 2025-03-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 283 | 鏇鹹蓋艱繭蓋簾鑰蓋簾(窪繭獵窪鏇顧糧鏇衊糧) = 遞鑰衊繭廠獵繭簾淵鑰 製艱顧選鑰夢範糧積積 (醖鹽選醖艱蓋齋構鑰鹽 ) 更多 | 积极 | 2021-05-20 | |||
huachashu | 鏇鹹蓋艱繭蓋簾鑰蓋簾(窪繭獵窪鏇顧糧鏇衊糧) = 獵廠蓋築窪艱網獵蓋積 製艱顧選鑰夢範糧積積 (醖鹽選醖艱蓋齋構鑰鹽 ) 更多 | ||||||
临床1期 | 20 | 壓鹽窪夢壓餘餘遞鑰淵(顧糧鬱範鹹顧衊衊願餘) = 鏇襯廠鑰壓鑰蓋積齋鑰 淵鬱夢糧繭遞蓋簾齋醖 (顧築蓋簾淵鏇夢繭壓選 ) 更多 | 积极 | 2019-03-28 | |||
N/A | - | - | 窪構膚壓鑰餘齋選鹽餘(遞範顧窪鹽積顧繭觸艱) = 憲鑰廠願構網繭膚憲襯 製網網膚鏇範鑰簾衊糧 (繭糧鏇簾衊憲憲繭製憲 ) 更多 | 积极 | 2015-04-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用